title: Peripheral vascular effects of beta-3 adrenergic receptor stimulation in conscious dogs.
abstract: To characterize the physiological function of the beta-3 adrenergic receptor subtype in vivo, the effects of a beta-3 adrenergic receptor agonist, BRL37344, were examined on systemic hemodynamics and regional blood flow distribution. They were compared with beta-1 or beta-2 adrenergic receptor stimulation using isoproterenol (ISO) in conscious dogs instrumented with aortic and left atrial catheters and ascending aortic flow probes. ISO, at a dose of 0.4 micrograms/kg/min i.v., reduced mean arterial pressure by 7 +/- 3% and increased total peripheral conductance by 145 +/- 12% and heart rate by 109 +/- 10%. BRL37344, at a dose of 8.3 micrograms/kg i.v., reduced mean arterial pressure by 9 +/- 4% and increased total peripheral conductance by 91 +/- 3% and heart rate by 63 +/- 5%. In the presence of selective beta-1 adrenergic receptor blockade with atenolol, ISO decreased mean arterial pressure by 20 +/- 5% and increased total peripheral conductance by 140 +/- 26% and heart rate by 60 +/- 12%. After combined beta-1 and beta-2 adrenergic receptor blockade with propranolol, ISO induced no significant effects. By contrast, after propranolol, BRL37344 still reduced mean arterial pressure by 13 +/- 2% and increased total peripheral conductance by 109 +/- 8% and heart rate by 45 +/- 5%. The beta-3 adrenergic receptor-mediated increase in total peripheral conductance (+146 +/- 8%) persisted after combined blockades, i.e., beta and alpha adrenergic, cholinergic, histaminergic, purinergic, prostaglandin and endothelium-derived relaxing factor blockades.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Harvard Medical School, Brigham & Women's Hospital, Boston, Massachusetts.
authors.forename: Y T
authors.initials: YT
authors.lastname: Shen
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.forename: S F
authors.initials: SF
authors.lastname: Vatner
mesh_terms: D058671:Adrenergic beta-1 Receptor Antagonists; D058672:Adrenergic beta-2 Receptor Antagonists; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D004285:Dogs; D004983:Ethanolamines / Q000494:pharmacology*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D009569:Nitric Oxide / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects*
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D058672:Adrenergic beta-2 Receptor Antagonists; D000318:Adrenergic beta-Agonists; D004983:Ethanolamines; D009569:Nitric Oxide; C057368:BRL 37344; D007545:Isoproterenol